NICX Clinical trials Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients Published August 21, 2025 at 05:30 AM Attachment Related Questions How will the positive Phase 3 results affect NICX's upcoming earnings and stock valuation? What are the expected regulatory timelines for FDA approval following the Denali trial? How does NCX 470's efficacy and safety profile compare to existing glaucoma treatments and potential market share? Find similar articles on Candlesense globenewswire